

CLAIMS

1. Use of metronidazole for the preparation of a pharmaceutical composition for treating cutaneous inflammation.
2. Use according to Claim 1, characterized in that the said cutaneous inflammation results from the secretion of at least one interleukin chosen from the group comprising IL-5, IL-6 and IL-10.
3. Use according to Claim 1 or 2, characterized in that the said cutaneous inflammation results from the secretion of two or three interleukins chosen from the group comprising IL-5, IL-6 and IL-10.
4. Use according to any one of Claims 1 to 3, characterized in that the said inflammation is the inflammatory component of rosacea and in that metronidazole is capable of modifying the secretion of at least one interleukin chosen from the group comprising IL-5, IL-6 and IL-10.
5. Use according to any one of Claims 1 to 4, characterized in that metronidazole is capable of modifying the secretion of two or three interleukins chosen from the group comprising IL-5, IL-6 and IL-10.
6. Use according to any one of Claims 1 to 5, characterized in that metronidazole inhibits the secretion of at least one interleukin chosen from the group comprising IL-5, IL-6 and IL-10.
7. Use according to any one of Claims 1 to 6, characterized in that metronidazole inhibits the secretion of two or three interleukins chosen from the group comprising IL-5, IL-6 and IL-10.
8. Use according to any one of Claims 1 to 7,

characterized in that the said pharmaceutical composition is a dermatological composition for topical application.

5 9. Use according to any one of Claims 1 to 8, characterized in that the composition is for treating at least one stage of rosacea.

10 10. Use according to any one of Claims 1 to 9, characterized in that the composition is for treating the first stage of rosacea.

15 11. Use according to any one of Claims 1 to 10, characterized in that the composition is for treating the second stage of rosacea.

12. Use according to any one of Claims 1 to 11, characterized in that the composition is for treating the third stage of rosacea.

20 13. Use according to any one of Claims 1 to 12, characterized in that the composition is for treating the fourth stage of rosacea.

25 14. Use according to any one of Claims 1 to 13, characterized in that the composition contains from about 0.0001% to 20% by weight and preferably from 0.1% to 2% of metronidazole, and more preferentially from about 0.75% to 1% by weight of metronidazole.

30 15. Use according to any one of Claims 1 to 14, characterized in that the said composition also contains another active agent chosen from the group of antibiotics, antibacterial agents, antiviral agents, 35 anti-parasitic agents, antifungal agents, anaesthetics, analgesics, anti-allergic agents, retinoids, free-radical scavengers, anti-pruriginous agents, keratolytic agents, anti-seborrhoeic agents, antihistamines, sulfides, immunosuppressant products

and anti-proliferative products.

16. Use according to any one of Claims 1 to 15,
characterized in that the composition contains an
5 additive chosen from the group of sequestrants,
antioxidants, sunscreens, preserving agents, fillers,
electrolytes, humectants, colorants common mineral or
organic acids or bases, fragrances, essential oils,
10 cosmetic active agents, moisturizers, vitamins,
essential fatty acids, sphingolipids, self-tanning
compounds, skin calmative and protective agents, pro-
penetrating agents and gelling agents, or a mixture
thereof.

**USE OF METRONIDAZOLE FOR THE PREPARATION OF A
PHARMACEUTICAL COMPOSITION FOR TREATING CUTANEOUS
INFLAMMATION**

The invention relates to use of metronidazole for the preparation of a pharmaceutical composition for treating cutaneous inflammation, and preferentially the inflammatory component of rosacea.